Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Monday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX opened at $0.50 on Monday. The stock has a 50 day simple moving average of $2.91 and a 200 day simple moving average of $4.01. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $14.78. The firm has a market capitalization of $6.49 million, a PE ratio of 0.42 and a beta of 0.51.

Institutional Trading of Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC boosted its holdings in Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Eagle Pharmaceuticals during the second quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $65,000. Fidelis Capital Partners LLC acquired a new position in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $76,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.